NCT03173976View on ClinicalTrials.gov

Anti-Osteoclast Therapy As Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

April 20, 2023

Study Completion Date

May 1, 2028

Conditions
Chondrosarcoma
Interventions
DRUG

Zoledronic Acid

Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

All Listed Sponsors
collaborator

Rising Tide Foundation

OTHER

lead

Mohammed Milhem

OTHER